 "Divis Lab gains on successful USFDA inspection of its Unit-2 facility at Visakhapatnam")
Divis Laboratories is trading higher by 2% at Rs 1,013 on the BSE after the drug firm said that the inspection conducted by the US health regulator of its Unit-2 facility at Visakhapatnam this month was successful.
"The company has had a successful inspection by the United States Food and Drug Administration (USFDA) for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February, 2016 with no observations," Divis Laboratories said in a filing to BSE.
The stock rallied nearly 4% to Rs 1,030 on the BSE in early morning trade. A combined 59,791 equity shares changed hands on the counter on the NSE and BSE till 09:35 AM.
"The company has had a successful inspection by the United States Food and Drug Administration (USFDA) for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February, 2016 with no observations," Divis Laboratories said in a filing to BSE.
The stock rallied nearly 4% to Rs 1,030 on the BSE in early morning trade. A combined 59,791 equity shares changed hands on the counter on the NSE and BSE till 09:35 AM.